Qbjective; The authors examined whether there are abnormalities in high-energy phospborous metabolism in the basal ganglia of schizophrenic patients. Method: In vivo 31P magnetic resonance spectroscopic imaging was performed on 18 chronic schizophrenic patients and 16 healthy comparison subjects. The percentages of total phosphorous signal for phosphomonoesters, inorganic phosphate, phosphodiesters, phosphoueatine, and $-ATP were calulated. Results; The mean percentages of $-ATP signal in the right and left basal ganglia were significantly lower for the schizophrenic patients than for the comparison group. No other group differences in phosphorous metabolites and no lateral asymmetries in the schizophrenic group were noted. Conclusions: This preliminary study provides support for abnormal highenergy phosphorous metabolism in the basal ganglia of schizophrenic patients.
T pathophysiology of schizophrenia on the basis largely of the dopamine hypothesis, regional effects of neuroleptics, and the importance of this brain region for processing cognitive and sensory information. Some positron emission tomography (PET) studies of schizophrenic subjects have demonstrated significantly lower basal ganglia glucose metabolism than in comparison subjects (1-3), whereas others have shown higher than normal glucose metabolism (4,5).
Given these PET findings, we thought it would be interesting to examine high-energy phosphorous metabofism of the basal ganglia by using in vivo 3lP magnetic resonance spectroscopy (MRS). Studies of schizophrenia using 31P MRS have focused primarily on the frontal and temporal lobes (6-8) and have not looked systematically at the basal ganglia. Therefore, we conducted a pilot study with 31P MRS imaging to determine whether there are differences in basal ganglia phosphorous metabolism between schizophrenic patients and healthy comparison subjects. We hypothe-126 sized, on the basis of the PET studies of basal ganglia glucose metabolism, that there would be abnormalities in measures of high-energy phosphorous metabolism in the schizophrenic group.
METHOD
The subjects were 18 male schizophrenic patients who met thr DSM-111-R criteria for schizophrenia and 16 male comparison sub jects. The schizophrenic subjecrs comprised 10 Caucasians, 31) blacks. and two Asians. and their mean age was 39.3 years (SD=6.1 ~ (TR) of 600 msec and time to echo (TE) of 30 msec, and the T,-weighted axial images included 16 slices (7.1-mm thickness, 1.2-mm gap1 with TR=2000 msec and TE=30 and 89 msec. A neuroradiologist blind to each subject's clinical StaNS evaluated the MRI scans for both rhe comparison subjects and patients to determine whether any structural abnormalities, asymmetry, or atrophy were present. The axid slices were angulated parallel to the canthomeatal plane observed on the sagittal slices to give a consistent anatomical perspective, which facilitated comparisons between the schizophrenic and normal groups. For the 31P MRS imaging, an inductively coupled, high-pass, quadrature birdcage head coil was used to provide homogeneous RF excitation and detection. The MRS procedures and experimental variables have been previously described for studies of the frontal and parietal lobes (10). A spin-echo sequence (TR=350 msec, TE=3.5 msec) was used. h4RS data volumes were reconstructed, and the effective voxel size was 25 cm3. A reference image of the total 31P signal was generated, and the higher resolution of the spatially registered MRS images was used to select two voxels in comparable locations for each subject in the right and left basal ganglia regions. The voxels comprised tissue from the head of the caudate, putamen, and part of the anterior limb of the internal capsule. The 31P spectra from these voxels were fit by the NMR-1 data processing software (New Methods Research, Inc., Syracuse, N.Y.). The percentages of total phosphorous signal for phosphomonoesters, inorganic phosphate, phosphodiesters, phosphocreatine, and P-ATP were calculated. The FATP resonance was selected to best represent the ATP concentration in tissue because, unlike the yand a resonances, it is free from signal contribution from other phosphatecontaining metabolites, such as ADP and nicotinamide adenine dinucleotide phosphates (11). The spectra were coded for blind processing by a single operator to eliminate interoperator variance.
The intraoperator correlation coefficients for spectral processing were as follows: phosphomonoesters, 0.75; inorganic phosphate, 0.99; phosphodiesters, 0.86; phosphocreatine, 0.95; and P-ATP, 0.95.
Repeated measures multivariate analysis of variance (MANOVA) was used for the major analyses. The dependent variable was the percentage of the total phosphorous signal for each metabolite, group was the between-subjects factor, and side (left versus right) was the within-subjects repeated measures factor. The phosphorous metabolites were analyzed in an exploratory fashion without correction for multiple comparisons. Regression analysis was used to examine the association of basal ganglia phosphorus metabolite values to length of illness in years and to neuroleptic medication dose in chlorpromah e equivalents.
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RESULTS
No structural abnormalities were noted on the MRI images of the patients or normal comparison subjects. The MRS measures of phosphorous metabolism are shown in table 1. The mean P-ATP values for the schizophrenic patients were significantly lower on the right and left sides than those for the normal subjects. Moreover, the mean P-ATP values on both the right and left were comparable for the patients who were (N=13) and were not ( N d ) taking neuroleptic medication. There were no other significant group differences. There was also no significant group difference in the total phosphorous signal. For the schizophrenic group, there were no significant correlations between any of the phosphorous metabolites and either the duration of illness in years or the neuroleptic dose in chlorpromazine equivalents.
DISCUSSION
This preliminary study demonstrates significantly lower concentrations of P-ATP in both the right and left basal ganglia of chronic schizophrenic patients than in normal comparison subjects. However, it is important to note that these findings arose from exploratory analyses that were uncorrected for multiple comparisons and must be replicated in future studies. Nevertheless, these findings may reflect a true concentration difference, ie., lower cellular ATP concentrations in the basal ganglia of schizophrenic patients than in comparison subjects. Such differences may indicate the occurrence of metabolic abnormalities within neurons, glial cells, or both. From a metabolic viewpoint, a low concentration of ATP indicates an imbalance between ATP production and ATP utilization from oxidative phosphorylation, Fujimoto et al. (12) reported a low concentration of p-ATP and a high concentration of phosphocreatine in the right basal ganglia of 17 chronic, medicated schizophrenic patients. These findings taken together support previous PET studies demonstrating basal ganglia metabolic abnormalities in schizophrenic patients. They suggest that further MRS studies of basal ganglia metabolism are warranted, particularly in medication-free patients. Along with our previous reports of abnormalities in high-energy phosphate metabolism in the frontal and temporal lobes (8, lo), these results also support the notion of specific, regional disturbances in oxidative metabolism in schizophrenia.
Since our study group consisted largely of chronic, medicated patients, it is conceivable that the low concentration of P-ATP might have been in part attributable to neuroleptic medication. Although some PET studies have suggested that neuroleptic medications increase basal ganglia metabolism (4,13-lS), the issue is less clear for MRS studies. Keshavan et al. (16) reported significant decreases from baseline measurements of ~1 -ATP in the left dorsal prefrontal cortex of eight firstepisode, drug-naive schizophrenic patients after they were treated for 4 weeks with neuroleptics. In another preliminary study (17) it was found that six newly diagnosed, medicated schizophrenic patients had significantly lower left prefrontal cortex P-ATP than did young comparison subjects but that 13 chronic, medicated schizophrenic patients showed no difference from middle-aged comparison subjects. This suggests that both illness chronicity and medication may influence brain high-energy phosphorous metabolism. In the present study, low basal ganglia ATP concentrations were present in both the five patients who had not received neuroleptic medication for 7 days and in those who were receiving neuroleptics. In addition, the absence of significant correlations between ATP and either the duration of illness or neuroleptic dose suggests that the abnormalities in ATP are not simply a consequence of illness chronicity or neuroleptic medication dose.
Our study had several limitations. Our subject groups were small, and it is not clear how studying different clinical subtypes of schizophrenia together may have affected our results. Future studies with more subjects will be able to address this question by examining any differences in basal ganglia metabolism between clinical subtypes. Second, abnormalities in the T1 or Tz of phosphorous metabolites in the basal ganglia region of schizophrenic subjects might also have contributed to the observed group difference. Third, a recognized limitation of in vivo spectroscopy is the low sensitivity of 31P MRS and the low concentrations of 31P metabolites, which limit the spatial resolution of 31P MRS. Fourth, the voxels selected for each subject contain varying percentages of gray matter, white matter, and CSF, which also need to be quantitatively determined. We do not believe that greater CSF space in the basal ganglia of schizophrenic patients would result in the specific dif-* 128 ference in ATP that we observed. If significantly greater CSF space were present in the schizophrenic patients than in the comparison group, we would expect lower concentrations of all phosphorous metabolites, as well as a lower total phosphorous signal, in the schizophrenic patients, and we did not observe this. We hope that in future studies MRI segmentation software can be combined with 31P MRS to determine the exact percentages of gray matter, white matter, and CSF in selected voxels. 
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